Abionic

Abionic SA is a company specializing in the development of ultra-rapid in vitro diagnostic tests, based in Lausanne, Switzerland. Abionic has developed the , a point-of-care diagnostic platform using its patented nanofluidic technology. The is implemented in intensive care units and emergency departments to enable early identification of sepsis using a proprietary biomarker, Pancreatic Stone Protein (PSP). The is also used in primary care for screening for the iron deficiency, respiratory allergies, and more recently for COVID-19 screening with an antigenic saliva and nasopharyngeal test.

Abionic SA is a company specializing in the development of ultra-rapid in vitro diagnostic tests, based in Lausanne, Switzerland. Abionic has developed the , a point-of-care diagnostic platform using its patented nanofluidic technology. The is implemented in intensive care units and emergency departments to enable early identification of sepsis using a proprietary biomarker, Pancreatic Stone Protein (PSP). The is also used in primary care for screening for the iron deficiency, respiratory allergies, and more recently for COVID-19 screening with an antigenic saliva and nasopharyngeal test. ==History== Abionic was founded in 2010¹ at the Swiss Federal Institute of Technology in Lausanne (EPFL, École Polytechnique Fédérale de Lausanne) by Dr Nicolas Durand and Dr Iwan Märki. In 2012, the company raised CHF 3.5 million in Series A funding. In 2014, Abiotic closed a CHF 8.2 million Series B funding round. Abionic’s first allergy test was launched in May 2015. The company received CE marks for the IVD CAPSULE PSP test for early sepsis diagnosis and the IVD CAPSULE Ferritin test in 2017. In the United States, Abiotic received FDA Approval for its first allergy panel test. In 2018, the company closed a Series C fundraising round totaling CHF 20 million. The company launched a sepsis impact study in April 2019. It took place in 14 ICUs in 4 EU countries, for the use of the IVD CAPSULE PSP test on the abioSCOPE in the ICUs. Patient trials in the United States were launched in 2020 to validate the results of the European trial. A CE mark for the abioSCOPE 2.0 was approved in 2019. Two years later, Abionic received a CE mark for the IVD CAPSULE COVID-19 Antigen test. In 2024, the FDA issued 510(k) clearance for the pancreatic stone protein (PSP) sepsis test. ==References== ==External links==

Text derived from https://en.wikipedia.org/w/index.php?oldid=1364040067 under CC BY-SA 4.0; modifications have been made.